Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03689699
Title Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Charles G. Drake

prostate cancer


BMS-986253 + Degarelix + Nivolumab

Degarelix + Nivolumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.